Final overall survival data from the phase 3 ROSELLA trial show relacorilant (Lifyorli) plus nab-paclitaxel improved outcomes in platinum-resistant ovarian cancer, with results presented at the 2026 SGO Annual Meeting. The combination reduced the risk of death by 35% versus nab-paclitaxel alone (HR 0.65; 2-sided P = .0004), extending median OS to 16.0 months from 11.9 months. Across prespecified subgroups, overall survival benefits were consistent, including patients with different prior therapy histories, PARP inhibitor exposure, and platinum-free interval lengths. The 12- and 18-month OS rates also favored the combination regimen. The report notes FDA approval in March 2026 and that relacorilant plus nab-paclitaxel is now listed as a preferred option in NCCN guidelines for platinum-resistant ovarian cancer. The update turns ROSELLA’s efficacy signals into a decision-grade benchmark for the next-line setting. By anchoring on mature OS, the latest ROSELLA readout tightens the evidence base for how the relacorilant mechanism may move earlier in treatment pathways, particularly for patients where platinum resistance limits options.